Stephen L. Chan
Chinese University of Hong Kong(CN)Chinese University of Hong Kong(HK)Prince of Wales Hospital(CN)University of Hong Kong(HK)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade(2014)2,678 cited
- → Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial(2018)2,498 cited
- → Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma(2018)2,297 cited
- → Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial(2019)1,782 cited
- → Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma(2022)1,333 cited
- → Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial